Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients

无容量 医学 耐受性 不利影响 内科学 肺癌 肿瘤科 癌症 免疫疗法
作者
Helena Linardou,Sofia Lampaki,Georgia-Angeliki Koliou,Athanassios Vozikis,Anastasios Boutis,Adamantia Nikolaidi,Ioannis Kontogiorgos,Pavlos Papakotoulas,Athina Christopoulou,Dionysios Spyratos,Dimitrios Bafaloukos,Amanda Psyrri,Anastasios Grivas,Anna Koumarianou,Karyofyllis Tsiakitzis,Davide Mauri,George S. Rigakos,Gerasimos Aravantinos,Panagiotis Papantoniou,Georgios Oikonomopoulos,Elena Fountzilas,Margarita-Ioanna Koufaki,Maria Kaparelou,Elias Liolis,Giannis Mountzios,P. Kosmidis,George Fountzilas,E. Samantas
出处
期刊:Anticancer Research [International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
卷期号:43 (6): 2799-2812
标识
DOI:10.21873/anticanres.16449
摘要

Nivolumab is an FDA-approved immune checkpoint inhibitor (ICI) for patients with advanced, pre-treated non-small cell lung cancer (NSCLC). However, treatment profiles and patient outcomes often differ in routine clinical practice while the financial impact of approved therapies is largely unknown. In this study, we investigated the efficacy, tolerability, and economic impact of nivolumab in real-world settings (RWS) in Greece.Patients diagnosed with advanced pre-treated NSCLC, receiving nivolumab were recruited from October 2015 until November 2019 across 18 different clinical centers in Greece. Endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Cost analysis was conducted using a third-party public-payer perspective (National Organization for Healthcare Services Provision; EOPYY).A total of 346 patients, median age 66.5 years, were included. With 43.4 months median follow-up, median PFS was 7.8 months and median OS 15.8 months. The 1-year OS rate was 56.5%, 2-year OS 38.8%, and 3-year OS 27.3%. The ORR was 29.5% and DCR 58.7%, with a median response duration of 26.8 months. Patients with objective response were more likely to experience long-term survival (HR=0.14, p<0.001). Only 8.4% of patients experienced grade 3-4 adverse events. The presence of immune-related adverse events was associated with improved OS (HR=0.77, p=0.043). Nivolumab-associated economic burden accounted for €2,214.10 per cycle for each patient, mainly attributed to drug-acquisition costs.This is the first report of real-world efficacy, safety, and economic burden of nivolumab in pre-treated patients with NSCLC in Greece. Indirectly compared to clinical trials, nivolumab was associated with improved efficacy in RWS, further supporting its use in clinical practice and providing insights on clinical prognosticators. The main cost component affecting the nivolumab economic burden was drug-acquisition costs, while toxicity-associated cost was negligible.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mr_Yang_完成签到,获得积分10
刚刚
小菜完成签到,获得积分10
刚刚
万能图书馆的应助被TT采纳,获得10
1秒前
1秒前
1秒前
坚定的寒天完成签到 ,获得积分10
2秒前
3秒前
刘营营完成签到,获得积分10
4秒前
4秒前
搜集达人的应助被灵山剑侠采纳,获得10
5秒前
忧郁的螺蛳粉完成签到,获得积分10
5秒前
xwx发布了新的文献求助10
6秒前
常富育发布了新的文献求助10
6秒前
三拾壹完成签到,获得积分10
6秒前
7秒前
钟意发布了新的文献求助10
7秒前
hbq完成签到,获得积分10
8秒前
8秒前
JOY完成签到,获得积分10
9秒前
精明雨真发布了新的文献求助20
9秒前
Daria发布了新的文献求助30
9秒前
tszjw168发布了新的文献求助10
10秒前
tong完成签到 ,获得积分10
10秒前
Hello的应助被开心德地采纳,获得10
10秒前
11秒前
handeny完成签到,获得积分20
12秒前
公爵发布了新的文献求助10
12秒前
谭小谭完成签到,获得积分20
13秒前
14秒前
ami完成签到 ,获得积分10
14秒前
从容的井完成签到,获得积分10
15秒前
15秒前
所所的应助被丁浩伦采纳,获得10
15秒前
15秒前
16秒前
baby完成签到,获得积分0
16秒前
kk发布了新的文献求助10
17秒前
fantasy的应助被Luxi采纳,获得10
18秒前
18秒前
Miles的应助被handeny采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189181
求助须知:如何正确求助?哪些是违规求助? 9576621
关于积分的说明 21848919
捐赠科研通 7787172
什么是DOI,文献DOI怎么找? 3435490
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482468